Immune Oncology Research Institute shared on LinkedIn:
“What if the most powerful weapon against cancer could come from the patient’s own immune system?
Sipuleucel-T demonstrated that this was possible, becoming the first FDA-approved therapeutic cancer vaccine for metastatic prostate cancer.
In their landmark review, Martin ‘Mac’ Cheever and Celestia (Tia) Higano describe how Sipuleucel-T improved overall survival without producing major changes in tumour size. This challenged traditional measures of treatment success and helped redefine how immunotherapy is evaluated, paving the way for today’s rapidly evolving immune-based cancer therapies.”
Title: PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Authors: Martin A. Cheever, Celestia S. Higano
Read The Full Article.
